Trial Outcomes & Findings for Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal (NCT NCT02244554)
NCT ID: NCT02244554
Last Updated: 2023-02-21
Results Overview
Physician's Global Assessment (min=0; Max=4) Higher scores indicate better outcomes
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
10 participants
Primary outcome timeframe
12 weeks
Results posted on
2023-02-21
Participant Flow
Unit of analysis: Sides of tattoos treated
Participant milestones
| Measure |
All Study Participants
Subject tattoos were divided into 2 sides for assignment into 2 arms for treatment by the Picosecond and Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) : active control arm and treatment arm. One side will receive treatment with the picosecond pulse duration and one side will receive treatment with the nanosecond pulse duration.
|
|---|---|
|
Overall Study
STARTED
|
10 20
|
|
Overall Study
Treatment With Picosecond Pulse Duration
|
10 10
|
|
Overall Study
Treatment With Nanosecond Pulse Duration
|
10 10
|
|
Overall Study
COMPLETED
|
10 20
|
|
Overall Study
NOT COMPLETED
|
0 0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal
Baseline characteristics by cohort
| Measure |
All Enrolled Subjects All Enrolled Subjects
n=10 Participants
Picosecond and Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
10 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: 12 weeksPhysician's Global Assessment (min=0; Max=4) Higher scores indicate better outcomes
Outcome measures
| Measure |
enLighten Laser Picosecond Pulse
n=10 Participants
Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
enLighten Laser: Picosecond pulse-duration pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
|
enLighten Laser Nanosecond Pulse
n=10 Participants
Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
enLighten Laser: Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
|
|---|---|---|
|
Level of Tattoo Clearing at 12 Weeks for Each Treatment Arm as Assessed by the Blinded Reviewers.
|
3 score on a scale
Standard Deviation .94
|
3 score on a scale
Standard Deviation .82
|
Adverse Events
enLighten Laser Picosecond Pulse
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
enLighten Laser Nanosecond Pulse
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
enLighten Laser Picosecond Pulse
n=10 participants at risk
Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
enLighten Laser: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
|
enLighten Laser Nanosecond Pulse
n=10 participants at risk
Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
enLighten Laser: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
|
|---|---|---|
|
Skin and subcutaneous tissue disorders
Erythema
|
100.0%
10/10 • Number of events 10 • 12 weeks
|
100.0%
10/10 • Number of events 10 • 12 weeks
|
|
Skin and subcutaneous tissue disorders
Edema
|
100.0%
10/10 • 12 weeks
|
100.0%
10/10 • 12 weeks
|
|
Skin and subcutaneous tissue disorders
Purpura
|
50.0%
5/10 • 12 weeks
|
50.0%
5/10 • 12 weeks
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place